Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 13, 2026
MASCC clinical practice statement: Prevention and management of acute radiation dermatitis using topical corticosteroidsHenry C Y Wong, Shing Fung Lee, Julie Ryan Wolf, et al.JAMA Dermatology|April 30, 2025
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical TrialYan Zhao, Melinda Gooderham, Bin Yang, et al.JAAD International|February 3, 2025
Optimizing the management of psoriasis in patients with skin of color: A Canadian Delphi consensusGeeta Yadav, Yvette Miller-Monthrope, Jaggi Rao, et al.International Journal of Radiation Oncology, Biology, Physics|January 12, 2025
Modified Delphi Consensus on Interventions for Acute Radiation Dermatitis in Breast Cancer: A Canadian Expert PerspectiveJeffrey Quoc Cao, Michael Yassa, Carmen Helena Avella Bolivar, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.The New England Journal of Medicine|October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo NodularisShawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2025
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled TrialByoung Chul Cho, Weimin Li, Alexander I Spira, et al.Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.Pageof 2